Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

Thymic carcinoma is a rare malignant disease and standard treatment for advanced or metastatic thymic carcinoma previously treated with platinum-based chemotherapy has not been established. Lenvatinib is a novel multi-targeted inhibitor of VEGFR, FGFR, RET, c-Kit, and other kinases. The aim of this...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2020-06, Vol.21 (6), p.843-850
Hauptverfasser:	Sato, Jun, Satouchi, Miyako, Itoh, Shoichi, Okuma, Yusuke, Niho, Seiji, Mizugaki, Hidenori, Murakami, Haruyasu, Fujisaka, Yasuhito, Kozuki, Toshiyuki, Nakamura, Kenichi, Nagasaka, Yukari, Kawasaki, Mamiko, Yamada, Tomoaki, Machida, Ryunosuke, Kuchiba, Aya, Ohe, Yuichiro, Yamamoto, Noboru
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis c-Kit protein Cancer therapies Chemotherapy Clinical trials Cytotoxicity Disease control Drug dosages Electrocardiography Fibroblast growth factor receptors Hematology Hypertension Laboratories Medical prognosis Metastases Metastasis Oncology Patients Platinum Registration Safety Solid tumors Studies Thymus Thyroid cancer Urinalysis Vascular endothelial growth factor receptors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!